Oral contraception rights sold by Galen for €37m

Pharmaceutical companies Galen and Barr this morning announced that they have closed two out of the three parts of their outstanding deal originally announced last September, which was under FTC review.

Oral contraception rights sold by Galen for €37m

Pharmaceutical companies Galen and Barr this morning announced that they have closed two out of the three parts of their outstanding deal originally announced last September, which was under FTC review.

Firstly, Galen has sold exclusive rights in the US and Canada for its Loestrin and Loestrin FE oral contraceptive products to Barr Pharmaceuticals for $45m (€37.1m).

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited